Scholarlink

Background <p>Pancreatic cancer is a highly lethal malignancy, usually diagnosed when metastasis is present. Detailed analysis of distant (DM) and lymph node (LN) metastasis patterns is crucial for prognosis. This study evaluated metastasis-specific prognosis in pancreatic cancer patients from 2010 to 2016 and developed a validated nomogram for survival prediction.</p> Methods <p>Data of patients with metastatic pancreatic cancer who received chemotherapy or radiotherapy were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Pearson’s chi-square test was utilized to analyze clinicopathological variables. Kaplan–Meier survival analysis and log-rank tests were employed to evaluate overall survival and prognostic outcomes. A nomogram for prognosis prediction was constructed using univariate and multivariate analyses, combined with the Cox proportional hazards regression model.</p> Results <p>Distant metastasis (DM) most commonly occurred in the liver (44.8%), followed by the bone (9.5%). Approximately 63.2% of patients had single-site metastasis, whereas 26.0% had metastases in two distant organs. Regional lymph node (LN) involvement was observed in 14.3% of pancreatic cancer patients, among whom only 3.7% concurrently had DM, with the liver being the most frequently involved organ, in which the liver was the most common organ. At the end of the follow-up period 152 patients in 1805 were alive. For pancreatic carcinoma patients with DM the median survival decreased to 4.0&#xa0;months, while with LN that was 31.05&#xa0;months. The nomogram was proven to be acceptable consistency in train and validation sets, and the c-index was 0.763.</p> Conclusion <p>We conducted a comparative analysis of clinicopathological characteristics and clinical outcomes among cases of metastatic pancreatic cancer. Furthermore, we developed a prognostic nomogram that demonstrated excellent performance in both the training and validation cohorts.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinicopathological features and survival outcomes of patients with different distant and lymph node metastasis in pancreatic cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月25日

查看全文
  • JianLin Lai,
  • Tiansheng Lin,
  • Lingpeng Tang,
  • Liangyu Wei,
  • Shizhao Chen,
  • Miao Gao,
  • Bofei Xu,
  • Junxuan Huang,
  • Zihan Qiu,
  • Haoxiang Zhang

摘要

Background

Pancreatic cancer is a highly lethal malignancy, usually diagnosed when metastasis is present. Detailed analysis of distant (DM) and lymph node (LN) metastasis patterns is crucial for prognosis. This study evaluated metastasis-specific prognosis in pancreatic cancer patients from 2010 to 2016 and developed a validated nomogram for survival prediction.

Methods

Data of patients with metastatic pancreatic cancer who received chemotherapy or radiotherapy were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Pearson’s chi-square test was utilized to analyze clinicopathological variables. Kaplan–Meier survival analysis and log-rank tests were employed to evaluate overall survival and prognostic outcomes. A nomogram for prognosis prediction was constructed using univariate and multivariate analyses, combined with the Cox proportional hazards regression model.

Results

Distant metastasis (DM) most commonly occurred in the liver (44.8%), followed by the bone (9.5%). Approximately 63.2% of patients had single-site metastasis, whereas 26.0% had metastases in two distant organs. Regional lymph node (LN) involvement was observed in 14.3% of pancreatic cancer patients, among whom only 3.7% concurrently had DM, with the liver being the most frequently involved organ, in which the liver was the most common organ. At the end of the follow-up period 152 patients in 1805 were alive. For pancreatic carcinoma patients with DM the median survival decreased to 4.0 months, while with LN that was 31.05 months. The nomogram was proven to be acceptable consistency in train and validation sets, and the c-index was 0.763.

Conclusion

We conducted a comparative analysis of clinicopathological characteristics and clinical outcomes among cases of metastatic pancreatic cancer. Furthermore, we developed a prognostic nomogram that demonstrated excellent performance in both the training and validation cohorts.